NewAmsterdam Pharma Company N.V.
NAMS
$35.26
-$0.59-1.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.24M | 64.01M | 47.14M | 45.56M | 33.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.24M | 64.01M | 47.14M | 45.56M | 33.59M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 35.24M | 64.01M | 47.14M | 45.56M | 33.59M |
| SG&A Expenses | 100.04M | 93.93M | 83.15M | 70.45M | 59.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 238.18M | 236.80M | 236.87M | 221.85M | 217.73M |
| Operating Income | -202.93M | -172.79M | -189.73M | -176.29M | -184.13M |
| Income Before Tax | -221.07M | -165.72M | -187.36M | -241.60M | -198.89M |
| Income Tax Expenses | 0.00 | -1.00K | -1.00K | -1.00K | 26.00K |
| Earnings from Continuing Operations | -221.07 | -165.72 | -187.36 | -241.60 | -198.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -221.07M | -165.72M | -187.36M | -241.60M | -198.92M |
| EBIT | -202.93M | -172.79M | -189.73M | -176.29M | -184.13M |
| EBITDA | -202.72M | -172.62M | -189.58M | -176.18M | -184.06M |
| EPS Basic | -2.02 | -1.59 | -1.86 | -2.58 | -2.25 |
| Normalized Basic EPS | -1.24 | -0.94 | -1.12 | -1.49 | -1.36 |
| EPS Diluted | -2.02 | -1.59 | -1.86 | -2.58 | -2.25 |
| Normalized Diluted EPS | -1.24 | -0.94 | -1.12 | -1.49 | -1.36 |
| Average Basic Shares Outstanding | 453.11M | 428.87M | 405.02M | 377.28M | 360.32M |
| Average Diluted Shares Outstanding | 453.11M | 428.87M | 405.02M | 377.28M | 360.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |